Numerous studies and investigations have called the safety of Infuse into question. Accordingly, it would not be surprising that there is less demand for the product.
New York, New York (PRWEB) February 22, 2013
The ongoing controversy surrounding Medtronic Infuse Bone Graft appears to have impacted sales at Medtronic, Inc.’s spinal division, Bernstein Liebhard LLP reports. According to the Memphis Business Journal, while overall earnings at the medical device maker jumped over 6% in the third quarter, revenue from spine devices fell by 3%. The company attributed the revenue drop to lower sales of Infuse Bone Graft.*
“Numerous studies and investigations have called the safety of Infuse into question. Accordingly, it would not be surprising that there is less demand for the product,” says Bernstein Liebhard LLP, a nationwide law firm currently evaluating Medtronic Infuse lawsuits on behalf of individuals who may have suffered respiratory problems, nerve damage, and wrongful death, allegedly associated with use of the product .
Medtronic Infuse Bone Graft Lawsuits
Medtronic Infuse Bone Graft was approved by the U.S. Food & Drug Administration (FDA) in 2002 for stimulating spinal bone growth in patients with a degenerative disease affecting the lower spine. In 2008, the FDA warned that Infuse Bone Graft had been associated with serious complications when used off-label in cervical spine fusions, including excessive swelling in the neck, compressed airways, difficulty breathing, problems swallowing and nerve damage.**
This past October, a U.S. Senate Finance Committee report raised disturbing questions about the research used to back Infuse. Among other things, Senate investigators charged that Medtronic deliberately manipulated the studies to downplay Infuse side effects and promote off-label use of the product. The report also found that Medtronic paid out $210 million in royalties, consulting fees, and other payments to the doctors who co-authored the Medtronic-sponsored Infuse studies.***
In 2011, The Spine Journal raised similar questions when it dedicated an entire issue to studying the risks of the recombinant bone morphogenetic protein-2, or BMP-2, used in Medtronic Infuse Bone Graft. The journal’s investigation found that more than a dozen Medtronic-funded studies downplayed or entirely omitted evidence of safety issues associated with Infuse.****
Bernstein Liebhard LLP is offering free lawsuit consultations to anyone allegedly injured by Medtronic Infuse Bone Graft. Victims of serious Infuse complications may be entitled to compensation for their medical care, pain and suffering, and other damages. A wealth of information regarding the potential dangers associated with Medtronic Infuse is available on Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/. For more information about Medtronic Infuse lawsuits, please contact one of our attorneys by calling 877-779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP